Korea Osimertinib Real world Evidence study to Assess safety and efficacy – PLUS

Trial Identifier: D5161R00005
Sponsor: AstraZeneca
Start Date: June 2019
Primary Completion Date: October 2024
Study Completion Date: October 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Chungcheongbuk-do, South Korea
South Korea Daejeon, South Korea
South Korea Gangwon State, South Korea
South Korea Incheon, South Korea
South Korea Jeollabuk-do, South Korea
South Korea Jeollanam-do, South Korea
South Korea Seoul, South Korea